Abstract 5475
Background
There are currently no good indicators of which patients with cancer will respond or not to immunotherapy. Novel computational analysis of computed tomography scans (CT) (i.e. radiomics) provides information about the tumour-infiltrating CD8 and predict response to immunotherapy. We aim to validate in an external cohort the VHIO CT-radiomics signature and to develop a combined radiomics-clinical signature that predicts the response to immune checkpoint inhibitors in patients with advanced solid tumours.
Methods
The VHIO CT-radiomics signature was developed in a population of 115 consecutive patients treated with immune checkpoint inhibitors (programmed-death protein 1 [PD-1] or programmed-death ligand 1 [PD-L1] inhibitors) monotherapy in phase I clinical trials (Cohort 1). The external validation included 62 consecutive patients with urinary bladder cancer treated with anti-PD-1 or PD-L1 monotherapy (Cohort 2). From the baseline CT, a target lesion per patient was delineated. Radiomics variables of first-order, shape, and texture were extracted. An elastic-net model combining radiomics and clinical features was implemented. The association between the radiomics score and changes in tumour shrinkage was assessed using Mann-Whitney analysis.
Results
In the Cohort 1 the CT-radiomics signature associates with response (area under the curve [AUC] of 0.81, p-value=2.74x10-5 and 0.72, p = 0.001 in the training and internal validation sets, respectively). In the external validation set (Cohort 2), the CT-radiomics signature predicts a response with an AUC of and 0.76 (p = 0.001). The model combining radiomics and clinical features has an AUC of 0.84 (p-value=5.04x10-9) for response prediction. Tumour homogeneity, hypodensity and spherical shape together with high lymphocytes and albumin and low neutrophils, corresponding to a high clinical-radiomics signature score, are indicators of tumour response. A higher CT-radiomics signature score is associated with a larger tumour shrinkage (p < 0.05).
Conclusions
CT-radiomics signature at baseline predicts the response to immune checkpoint inhibitors. Integrating radiomics and clinical data improved the response prediction capacity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by the Banco Bilbao Vizcaya Argentaria and Fundacio La Caixa. RPL is supported by a Prostate Cancer Foundation Young Investigator award.
Disclosure
J. Martín Liberal: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ipsen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pierre Fabre; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb. R. Morales Barrera: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi Aventis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Janssen; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck Sharp & Dohme; Advisory / Consultancy, Speaker Bureau / Expert testimony: Asofarm; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Astellas; Travel / Accommodation / Expenses: Pharmacyclics; Travel / Accommodation / Expenses: Clovis Oncology; Travel / Accommodation / Expenses: Lilly. E. Elez: Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: Sanofi; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Servier and Amge ; Research grant / Funding (self): Merck. E. Felip: Honoraria (self): AbbVie; Honoraria (self): AstraZeneca; Honoraria (self): Blue Print Medicines; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Celgene; Honoraria (self): Eli Lilly; Honoraria (self): Guardant Health; Honoraria (self): Janssen; Honoraria (self): Medscape; Honoraria (self): Merck KGaA; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Takeda; Honoraria (self): Touchtime. J. Tabernero: Advisory / Consultancy: Array Biopharma; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: BeiGene; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Chugai; Advisory / Consultancy: Genentech, Inc; Advisory / Consultancy: Genmab A/S; Advisory / Consultancy: Halozyme; Advisory / Consultancy: Imugene Limited; Advisory / Consultancy: Inflection Biosciences Limited; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Kura Oncology; Advisory / Consultancy: Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Menarini; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Merus; Advisory / Consultancy: Molecular Partners; Advisory / Consultancy: Novartis; Advisory / Consultancy: Peptomyc; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Pharmacyclics; Advisory / Consultancy: ProteoDesign SL; Advisory / Consultancy: F. Hoffmann-La Roche Ltd; Advisory / Consultancy: Sanofi; Advisory / Consultancy: SeaGen; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Servier; Advisory / Consultancy: Symphogen; Advisory / Consultancy: Taiho; Advisory / Consultancy: VCN Biosciences; Advisory / Consultancy: Biocartis; Advisory / Consultancy: Foundation Medicine; Advisory / Consultancy: HalioDX SAS. R. Dienstmann: Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Symphogen; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Amgen; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Servier; Research grant / Funding (self): Merck. All other authors have declared no conflicts of interest.
Resources from the same session
4387 - Machine learning-assisted prognostication based on genomic expression in the tumor microenvironment of estrogen receptor positive and HER2 negative breast cancer
Presenter: Yara Abdou
Session: Proffered Paper session: Artificial intelligence and machine learning as tools for practice in oncology
Resources:
Abstract
Slides
Webcast
Proffered Paper session: Artificial intelligence and machine learning as tools for practice in oncology - Invited Discussant: The perspective of the mathematician
Presenter: Nikos Paragios
Session: Proffered Paper session: Artificial intelligence and machine learning as tools for practice in oncology
Resources:
Slides
Webcast
Proffered Paper session: Artificial intelligence and machine learning as tools for practice in oncology - Invited Discussant: The impact for the clinician
Presenter: Christos Sotiriou
Session: Proffered Paper session: Artificial intelligence and machine learning as tools for practice in oncology
Resources:
Slides
Webcast